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Alginates: From the ocean to gastroesophageal reflux 
disease treatment
The management of gastroesophageal reflux (GERD) 
disease is based on proton-pump inhibitor (PPI) thera-
py. However, alginates are an alternative therapeutic ap-
proach, either as a monotherapy or in combination with 
PPIs that play an important role in treatment. In this ar-
ticle, we evaluated the following topics in relation to al-
ginates:
1. Definition and epidemiology of GERD
2. Production and mode of action of alginates
3. Efficacy of alginate monotherapy for the treatment 
of mild GERD symptoms
4. The role of alginates in combination with PPIs in pa-
tients with severe or PPI-unresponsive GERD
5. The efficacy of alginates in regurgitation-dominant 
GERD
6. Alginates in the management of atypical GERD 
symptoms
7. Long-term and/or on-demand use
8. The role of alginates in the step-down or cessation of 
PPI therapy
9. Alginates in the treatment of GERD in children
10. Alginates in pregnancy and lactation
11. Safety
Definition and epidemiology of gastroesophageal reflux 
disease
Gastroesophageal reflux disease (GERD) is defined as a 
“condition which develops when the reflux of gastric con-
tent causes troublesome symptoms or complications” (1). 
However, there is no accepted universal definition of the 
symptoms of GERD and its complications. Additional-
ly, there are significant differences among various racial 
groups in terms of the understanding and the experience 
of the symptoms of GERD. For example, there is no word 
for heartburn in Dutch, Malay, Mandarin, Chinese, or Ko-
rean. In an interracial study by Spechler et al. (2) most of 
the participants (65.9%) did not understand the meaning 
of the term heartburn, while 22.8% of patients who de-
nied having heartburn in fact experienced symptoms that 
physicians might consider to be heartburn.
Recently, an international study group defined pathologi-
cal GERD as the presence of at least one of the following 
criteria: grade C or D esophagitis in upper gastrointesti-
nal (GI) endoscopy, esophageal peptic stricture, Barrett’s 
mucosa longer than 1 cm and esophageal acid exposure 
>6% in 24-hour impedance-pH-metry (3). According to 
this definition, there are a tremendous number of pa-
tients stay in the gray zone.
Epidemiology of GERD and its complications 
GERD has a global impact on health and impairs the 
health-related quality of life of a substantial proportion 
of the global population. A recent meta-analysis showed 
that there was a statistically significant increase in the 
prevalence of GERD worldwide in the last 20 years (4). 
The pooled prevalence of GERD symptoms that occurred 
at least weakly reported from population-based studies 
worldwide is approximately 13%, but there is consider-
able geographic variation. Because there is heterogeneity 
in study designs, it is difficult to accurately estimate the 
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prevalence of GERD. However, most studies have revealed 
that the prevalence of GERD appears to be highest in 
South Asia and Southeast Europe (> 25%) and lowest in 
Southeast Asia, Canada, and France (<10%) (5) (Figure 1).
In Turkish GERD epidemiological studies, the prevalence 
of GERD was found to be 20% (6), 19.3% (7), 12.5% (8), 
and 22.8% (9,10) when evaluated with the Mayo ques-
tionnaire. The GERD Questionnaire (GERD-Q) was used 
in one study, and the prevalence was found to be 24.7% 
(11). According to these 5 studies, the pooled prevalence 
of GERD in Turkey was calculated to be 23%. Regurgita-
tion was more common than heartburn in all of the stud-
ies. In the cumulative evaluation, the prevalence rates 
were 23% for regurgitation and 19% for heartburn (12). 
These data confirm that the prevalence rate of GERD 
in Turkey is similar to that in European countries, while 
regurgitation as the predominant symptom is similar to 
studies from Asian countries.
Erosive esophagitis (EE) is one of the most common 
complications of GERD. The prevalence difference of EE 
in Western countries is larger than Eastern countries in 
symptomatic patients. In 3 population-based studies, 
the prevalence of EE in symptomatic GERD ranged from 
6.4-15.5%, while the prevalence of EE in asymptomatic 
patients ranged from 6.1-9.5% (13-15). Although EE is 
more common in Western countries, the distribution of 
EE severity seems to be similar in both geographic areas 
(14,16). Only a small proportion of patients with EE have 
severe esophagitis findings in endoscopy (13-16). In Tur-
key, the prevalence of EE in symptomatic GERD patients 
seems to be similar to that observed in Western coun-
tries. Additionally, the distribution of EE severity is not 
different from that in the rest of the world (17).
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Figure 1. Distribution of GERD prevalence worldwide (12).
As seen in GERD, the prevalence of Barrett’s esophagus 
(BE) is higher in Western countries (18) than in Eastern 
countries. Gerson et al. (19) found that short-segment 
BE with histologically confirmed intestinal metaplasia 
was found in 17% of asymptomatic patients who under-
went colonoscopy screening. In another study, the prev-
alence of BE was 65 out of 961 (6.8%) patients, which 
included 12 (1.2%) patients with long-segment BE (20). 
In contrast to the abovementioned data, the findings of 
a recent meta-analysis showed that the pooled preva-
lence of histologic BE in Asian countries was similar to 
that in Western countries (1.3% vs 1.6%). Additionally, 
the prevalence of low-grade dysplasia, high-grade dys-
plasia, and esophageal adenocarcinoma (EAC) in histo-
logic BE in Eastern countries was similar to that in West-
ern countries (21). The prevalence of histopathologically 
confirmed BE in Turkish cohorts (0.6%) was much lower 
than that in Eastern and Western cohorts (9,17,22,23). 
In a study comparing immigrants and Dutch inhabitants 
in the Netherlands, reflux disease was less prevalent in 
immigrants, who were mostly of Turkish descent, than 
among native Dutch individuals. Additionally, there were 
no patients with BE among the Turkish immigrants (24).
The prevalence of EAC varies geographically, and sever-
al studies have documented that the incidence of EAC 
has tended to increase in the last 20 years in North-
ern and Western Europe, Northern America, and Ocea-
nia. The highest incidence of EAC was observed in the 
United Kingdom (7.2/100,000 person-years in men and 
2.5/100,000 person-years in women), the Netherlands, 
Ireland and the United States, in that order. The lowest 
incidence rates were observed in sub-Saharan Africa 
(25). GERD is a common disorder, but there are some dif-
ferences according to the geographical areas. These dif-
ferences might have an impact on the selection of medi-
cations, similar to regurgitation-dominant disease.
Production and mode of action of alginates
Alginate-based pharmaceutical formulations have been 
successfully used to treat the symptoms of GERD for de-
cades and have a rapid onset of symptom relief. In the last 
twenty years, the knowledge and awareness of GERD has 
grown from the classical reflux symptoms of heartburn 
and regurgitation to the symptoms of extraesophageal 
reflux (EER), also known as airway reflux, silent reflux and 
laryngopharyngeal reflux disease (LPR). This increased 
awareness has led to a far greater understanding of the 
reflux of gastric contents in the airways, lungs, and ears, 
leading to a myriad of additional ear, nose, and throat 
(ENT) and respiratory symptoms, which we now know 
may be indications for the use of alginate-based phar-
maceutical products. Research and clinical studies have 
demonstrated that upwards of 40% to 60% of Western 
populations can benefit from alginate-based products, 
and this benefit is quickly growing in other regions of the 
world where reflux disease is now recognized as a real and 
growing problem.
Alginates naturally occur as structural polysaccharides in 
brown algae (seaweed). The nature of alginates as well as 
the production and mode of action are summarized be-
low.
1. The harvesting of alginates
There are many different alginates with different chemi-
cal structures and properties, and the function of the al-
ginate determines the application and the end product 
for which it is used. Today, alginate production is mainly 
based on harvested Macrocystis pyrifera in the USA, Durvi-
llea spp. and Lessonia spp. in Chile and small amounts of 
Ecklonia spp., Eisenia spp. and Laminaria japonica in the 
Far East. In Europe, the raw materials include Laminaria 
digitata in France and Ascophyllum nodosum and Lam-
inaria hyperborea in Norway. The worldwide distribution 
of the various seaweeds that have been commercialized 
is illustrated in Figure 2.
The diversity of the seaweed harvest sites is reflected in 
the differences in the characteristics and properties of 
the various alginates. The most important seaweed in 
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Figure 2. The world distribution of the various seaweeds that have 
been commercialized.
Laminaria hyperborea
Laminaria digitata
Laminaria japonica
Ascophyilum nodusum
Eckionia
Lessonia trabeculata and nigrescens
Macrocystics pyrifera
terms of pharmaceutical products is Laminaria hyper-
borea. The mechanization of the harvest of this particular 
seaweed species began in 1964, and the method of har-
vesting has developed along the west coast of Norway, in 
an area from the south to the Lofoten Islands in the north 
of the country (Figure 2, 3).
2. Chemical composition and physical properties of al-
ginate
The chemical composition of alginates is variable to a 
certain extent. The composition varies according to the 
seaweed species and even within the different parts of 
the same plant. The composition is also affected by sea-
sonal changes and by the roughness of the sea.
Alginate occurs both in brown algae and in certain bac-
teria and can be considered both a phycocolloid and a 
microbial polysaccharide. Alginates belong to a family of 
linear copolymers containing 1,4-linked β-D-mannuronic 
acid (M) and 5-epimer α-L-guluronic acid (G). The distri-
bution of M and G in alginate chains gives rise to three 
different block types, namely, poly-M blocks, poly-G 
blocks and alternating M-G-M-G blocks i.e., MG blocks. 
Alginates isolated from different algae can vary both in 
the monomer composition and the block arrangement, 
and these variations are also reflected in the properties 
of the alginate.
Alginate forms strong gels with divalent cations, such as 
Ca2+, giving both strength and flexibility to the algal tis-
sue. While the viscosity depends mainly on the molecular 
size, the affinity for cations and the gel-forming prop-
erties of the alginate are mostly related to the guluronic 
monomer content. When two guluronic acid monomer 
residues are adjacent in the polymer, they form a binding 
site for polyvalent cations. The content of the G-blocks is 
therefore the main structural feature contributing to the 
gel strength and stability, thus making the stem of Lam-
inaria hyperborea ideal for use as a raft-forming agent to 
suppress gastric reflux.
Further information regarding the detailed chemical 
composition of alginates can be obtained by nuclear 
magnetic resonance (NMR) spectroscopy. By high-res-
olution NMR, it is possible to determine the complete 
M-G profile of an alginate, including information on the 
three neighboring units and the average block lengths. 
Table-1 shows the typical M and G profiles for alginates 
from different seaweeds, clearly indicating that the al-
ginate characterization varies between seaweed spe-
cies.
3. Alginates are different
Alginates produced from different seaweeds have differ-
ent chemical compositions and physical properties. Only 
certain alginates have the right characteristics to be used 
to manufacture effective reflux-suppressant products. 
The mode of action of these products is physical rather 
than pharmacological.Figure 3. Harvesting mechanization of Laminaria hyperborea
Raw material FG FM FGG FMG+GM FMM FGGG FMGM FGGM NG>1 Gel strength
Laminara hyperborea (stem) 0.70 0.30 0.57 0.26 0.17 0.52 0.04 0.04 17 High
Laminara hyperborea (leaf) 0.55 0.45 0.26 0.38 0.36 0.29 0.12 0.05 9 Medium
Macrocystis pyrifeira 0.39 0.61 0.16 0.46 0.38 0.12 0.20 0.03 6 Medium - low
Ascophyllum nodusum 0.36 0.64 0.16 0.40 0.44 0.12 0.15 0.15 4 Medium - low
Lessonia nigrescens 0.40 0.60 0.22 0.38 0.40 0.20 0.14 0.04 7 Medium - low
Lessonia trabeculata 0.67 0.33 0.55 0.23 0.22 0.50 0.07 0.05 12 High - medium
Laminaria japonica 0.34 0.66 0.16 0.36 0.48 0.13 0.15 0.03 6 Medium - low
Laminaria digitata 0.41 0.59 0.25 0.32 0.43 0.20 0.11 0.05 6 Medium - low
Durvillea antarctica  0.31 0.69 0.18 0.27 0.56 0.14 0.09 0.04 6 Low
Table 1. Typical M and G profiles for alginates from different seaweed species.
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The three active ingredients of the most effective prod-
ucts are sodium (Na) alginate (Laminaria hyperborea 
stem), Na bicarbonate (HCO3) and calcium (Ca) carbon-
ate (CO3). These substances interact to form a strong, 
coherent, voluminous, buoyant alginate raft when they 
are introduced to the acidic gastric environment. The 
raft is responsible for suppressing reflux and relieving the 
symptoms of heartburn and GERD. 
The experience of alginate product manufacturing has 
shown that the type of alginate used is very important for 
the formation of buoyant, voluminous, strong and coher-
ent rafts. Only alginates with a very low molecular weight 
and high gel strength are suitable for the manufacture 
of effective reflux-suppressant products. Alginates from 
different species of seaweed and different parts of the 
same seaweed, for example, the leaf, have different mo-
lecular compositions, and these differences in composi-
tion can determine whether or not the product forms a 
coherent, buoyant raft or whether it forms a raft at all.
Table 2 shows the rafting performance of products pre-
pared with low-molecular weight Na alginates conform-
ing to the European Pharmacopeia monograph that were 
derived from different seaweed sources. The rafts were 
formed by adding a 20-mL dose of product to 150 mL of 
0.1 M HCl and incubating the mixture at 37°C for a period 
of 30 minutes. Table 2 shows that only the product made 
with Na alginate extracted from the stems of Laminaria 
hyperborea was able to form strong, coherent, voluminous 
and highly buoyant rafts. This product also had a larger raft 
thickness and acid neutralization capacity (26). Products 
Figure 4. Mode of action of sodium alginate
Alginate source (seaweed species) Raft description Raft volume Raft buoyancy Raft strength Raft shrinkage
Ascophyllumnodosum No raft formed - - - -
Durvillea antartica 80% Weak, inconsistent 38 mL Floats below 4 g high
Lessonia nigrescens 20%   liquid surface
Lessonia nigrescens Weak, uniform 55 mL Floats below 7 g medium
   liquid surface
Laminaria hyperborea (stem) Strong, coherent 60 mL Floats below 12 g minimal
 uniform  liquid surface
Table 2. The rafting performance of product batches prepared with Na alginates from different seaweeds.
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made with alginate extracted from the other sources in the 
table either formed weaker, inconsistent rafts with lower 
volumes and poor buoyancy or did not form rafts at all.
4. Mode of action
Alginates have a unique, nonsystemic, physical, rather 
than pharmacological, mode of action, and the selection 
of the correct alginate is essential for the performance in 
several key areas, as listed below.
1. Prevention of gastric reflux.
a) Suppression of gastric reflux. The G-block struc-
ture of an alginate contributes to the gel strength, 
which results in a reaction between Na alginate 
and the acid present in the stomach, producing a 
low-density viscous gel that floats on top of the 
stomach. This forms a physical barrier that pro-
tects the delicate esophageal mucosa and the 
airways from the gastric refluxate (26,27).
b) Prevention of postprandial reflux. The physical 
barrier formed by alginate is also very important 
for eliminating or displacing the acid pocket that 
has been identified in GERD patients (Figure 5). 
The acid pocket forms at the gastroesophageal 
junction after a meal and consists of an unbuff-
ered, highly acidic gastric juice and has patho-
physiological relevance in GERD. A strong algi-
nate raft can cap the acid pocket and reduce or 
even prevent postprandial acid reflux (28,29).
2. Inhibition of pepsin and bile acids. Alginate can re-
move both pepsin and bile acids from gastric reflux-
ate, limiting their diffusion and specifically affecting 
the enzymatic activity of pepsin (30).
3. Topical protection. Alginates play a major role in the 
topical protection of the vulnerable and sensitive 
esophageal mucosa, reducing the risk of inflamma-
tion as a result of the components of the gastric re-
fluxate, such as acid, pepsin and bile acids. Suspen-
sions of the correct Na alginate can form adherent 
viscous layers on contact with the esophageal mu-
cosa and demonstrate bioadhesive potential in this 
area, which is highly susceptible to potential damage 
from the components of gastric reflux (31,32). In a 
recent study by Woodland et al. (31), 3D-cell culture 
was used to analyze the protective effect of a top-
ically applied alginate solution. The apical surface 
Figure 6. Microscopy at 20x under an epifluorescence microscope, 
showing fluorescein-labeled alginate on the luminal surface of the 
biopsy mucosa after 1 hour of washing in a neutral solution. Nuclei 
are stained with DAPI. Yellow arrows indicate example thickness 
measurements.
Figure 5. Acid pocket, as measured with a pH catheter, in the proximal stomach following food intake (Ege University School of Medicine, 
Motility Lab).
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was covered and protected by alginate or a control 
solution. Similar to these models, human esophageal 
biopsies were placed into Ussing chambers and were 
then coated. A pH 3 bile acid solution was applied, 
and transepithelial resistance (TER) values were mea-
sured in both models. The luminal sides of all tissues 
were covered with adherent alginate. The decrease in 
TER in alginate-coated tissues was significantly lower 
than that in the controls. This finding implies that the 
application of alginates augments tissue resistance in 
vitro (Figure 6).
Efficacy of alginate monotherapy for the treatment of 
mild GERD symptoms
Heartburn and regurgitation are typical symptoms of 
GERD and reduce the quality of life for millions of people. 
Approximately 50-80% of patients have symptomatic 
(endoscopy-negative or nonerosive) or mild erosive GERD 
(grade I, Savary/Miller or Los Angeles (LA)-A, B) (12,33). 
Acid suppression is the mainstay of therapy for GERD, 
and proton-pump inhibitors (PPIs) are the most potent 
acid-suppressing drugs. However, in some patients, es-
pecially those with nonerosive reflux disease (NERD), ac-
id-suppressive therapy with PPIs is not as successful.
Alginates are medications that work through an alterna-
tive mechanism, by displacing the postprandial gastric 
acid pocket. The acid pocket is a short zone of unbuffered 
highly acidic gastric juice that occurs below the esoph-
agogastric junction after meals. Conventional mecha-
nisms, such as transient lower esophageal sphincter re-
laxation (TLESR) and hiatal hernias, may increase GERD 
Figure 7. Algorithm for patients with typical reflux symptoms and indications for alginate in the treatment of GERD (adapted from 40).
UGEI: Upper-GI endoscopic indications; Sx: symptom; AA: antacids.
Indications for UGIE: >50 years old, Sx duration >5 years, dysphagia, odynophagia, GI system (GIS) bleeding, weight loss, recurrent vomiting, unexplained anemia, 
first-degree relatives with upper-GI cancer.
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by enhancing the acid pocket (29,34). In the presence 
of gastric acid, alginate forms a foamy gel that is similar 
to a raft floating on the surface of the gastric contents, 
and this barrier-like gel prevents acid reflux in GERD. In 
vitro and in vivo studies have demonstrated an immedi-
ate onset of therapeutic effects with alginate (within 1 
hour of administration) that is faster than that of a PPI or 
an H2 receptor antagonist (H2RA) (35). Compared with 
antacids, alginate-based formulations are more effective 
in controlling postprandial esophageal acid exposure and 
in relieving reflux symptoms, including heartburn, regur-
gitation, vomiting and belching, with a longer duration 
(36-38). Alginate-based formulations are also noninfe-
rior to omeprazole in achieving a heartburn-free period 
in patients with moderate episodic heartburn (39). Addi-
tionally, the Turkish reflux study group consensus report 
recommended alginate monotherapy as an initial therapy 
for patients with mild GERD (40) (Figure 7).
Alginate monotherapy has been shown to be superior to 
placebos and antacids for decreasing GERD symptoms in 
patients with NERD in several studies (41,42). In a recent 
meta-analysis (33), alginate was shown to be superior to 
the placebo in one study, while it was more effective than 
antacids in two other studies. Additionally, the effect of 
alginate was comparable to that of omeprazole in three 
different studies (39,43,44) (Table 3).
In a study by Giannini et al. (45), symptom resolution was 
higher and the speed of action was faster in the alginate 
group than that in the antacid group. In another more 
recent study, the level of complete symptom relief was 
similar in patients receiving omeprazole or alginate (60% 
vs. 56.7 for intention-to-treat (ITT), p=0.7, respectively 
and 66.7% vs 65.4% for per protocol, p=0.7, respective-
ly). In an open-label placebo-controlled study, alginate 
significantly decreased heartburn frequency compared 
with placebo (46). A double-blind randomized controlled 
trial showed that Gaviscon, an alginate-antacid formula-
tion, achieved more relief of reflux symptoms, including 
heartburn and regurgitation, in patients with both NERD 
and EE (47).
In conclusion, alginate is superior to placebos and antacids 
for the treatment of mild GERD, and alginate monother-
apy seems to be beneficial as an initial treatment for mild 
GERD. There are limited data comparing alginate and PPIs 
for the treatment of mild GERD. The only agent tested in 
a limited number of studies was omeprazole, and the ef-
fect of omeprazole was comparable to that of alginate for 
decreasing typical GERD symptoms. Further studies with 
next-generation PPIs are required to confirm these data.
The role of alginates combined with PPIs in patients 
with severe or PPI-unresponsive gastroesophageal re-
flux disease
There are different definitions of severe symptomat-
ic GERD in the literature. According to the Turkish Re-
flux Study Group Consensus Report, moderate/severe 
symptomatic reflux was defined as 3 or more heartburn 
or regurgitation in a week, affecting daily activities (40). 
Endoscopic severe esophagitis is defined as LA grade C 
or D esophagitis (48). Although several studies have an-
alyzed the efficacy of adding alginic acid to PPIs, most of 
these studies included patients who did not adequately 
respond to PPIs or who had symptomatic breakthroughs 
(49-51). For instance, in a multicenter study, improve-
ments in the Heartburn Reflux Dyspepsia Questionnaire 
(HRDQ) reflux score and the number of night-time symp-
toms in patients who remained symptomatic despite sin-
gle-dose PPIs were significantly higher in the PPI+Gavis-
con Advance group than those in the PPI+placebo group. 
The authors of this study concluded that adding alginate 
to the treatment plan can decrease the burden of re-
flux symptoms in PPI-unresponsive patients (50). One 
of the major limitations in these studies was the lack of 
the symptomatic or endoscopic stratification of patients 
as having mild or moderate/severe disease before ran-
domization and that all of the patient data was pooled 
together (49-51).
Sodium alginate combined with omeprazole has been 
shown to be better than omeprazole alone in terms of 
complete symptom resolution at the end of the study 
(56.7% vs 25.7%, p<0.05) in Japanese patients with 
NERD. In that study, the symptom frequency was at least 
2 days per week during the 1-month period before enter-
ing the study (49) (Figure 8).
  Odds ratio (OR)  
  (95% confidence 
Study  Comparator interval (CI))
Beeley et al. (1972) Placebo 4.89 (1.83-13.07)
Chevrel et al. (1980) Antacid 17.97 (6.15-52.51)
Lai et al. (2006) Antacid 3.86 (1.81-8.22)
Goves (1998) PPIs 0.24 (0.15-0.37)
Pouchain et al. (2012) PPIs 0.68 (0.41-1.13)
Chiu et al. (2013) PPIs 1.11 (0.62-1.99)
PPIs: Proton-pump inhibitors.
Table 3. Alginate monotherapy vs other therapies for GERD 
treatment.
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PPI therapy is a first-line approach to ensure endo-
scopic healing and symptom control in patients with 
GERD. However, a substantial subgroup of patients with 
well-defined GERD will continue to experience reflux 
symptoms despite adequately dosed PPI therapy (52,53). 
While there is no universal definition for PPI “failure,” the 
presence of heartburn and/or regurgitation and an im-
paired quality of life despite adequate doses of PPIs may 
be indicative of PPI failure. The Turkish reflux study group 
defined PPI unresponsiveness as “in patients without 
alarm symptoms, if there is less than 50% recovery in 
typical reflux symptoms after 4 weeks qd PPI treatment 
following nonresponsive 4-week bid PPI treatment” (40). 
These patients are considered to have refractory GERD 
(rGERD). Several studies have shown that adding alginate 
to existing PPI therapy aids in the control of GERD symp-
toms (49-51). In a multicenter study of 134 patients with 
GERD symptoms, adding an alginate-antacid suspension 
to once-daily PPI treatment decreased the severity and 
frequency of heartburn, the frequency of regurgitation 
and the number of days with night-time symptoms.
Although PPIs have become the main therapy for severe 
symptomatic GERD or severe EE, it has been well doc-
umented that the durability of this therapeutic effect 
is less notable. In a recent systematic literature review, 
it was reported that breakthrough symptoms after PPI 
treatment were found in 30-60% (54). The effect of 
alginic acid as an add-on treatment was compared with 
the effect of a placebo in GERD patients with an insuf-
ficient control of heartburn and/or regurgitation despite 
a once-daily PPI in two parallel study arms (exploratory 
study arm and confirmatory study arm). Symptomatic 
improvement was observed with an add-on alginic ac-
id-antacid combination, but there was no significant dif-
ference in the response to this treatment vs that to the 
placebo in the confirmatory arm (51-48%, respectively) 
(OR (95% CI): 1.15 (0.69-1.91), p=0.594), while there was 
a significant difference in the exploratory arm (75-36%, 
p<0.05) (51).
Ranaldo et al. (55) showed that adding alginate to the 
treatment improved GERD symptoms in patients who 
were refractory to 8 weeks of PPI treatment and had 
weak acid reflux that was documented with multichan-
nel intraluminal impedance pH (MII-pH) monitoring.
The overall results from these studies provide evidence 
that add-on alginate helps reduce reflux symptoms in pa-
tients with an insufficient response to PPIs. This effect 
is particularly high in patients with weak acid/non-acid 
reflux.
The efficacy of alginates in regurgitation-dominant 
gastroesophageal reflux disease
The typical symptoms of GERD include heartburn and 
regurgitation. Regurgitation is defined as the perception 
of the flow of refluxed gastric content into the mouth or 
hypopharynx (1). Although PPIs have satisfactory ther-
apeutic effects for heartburn, the relative therapeutic 
gain for regurgitation obtained by PPIs is evidently lower 
than the therapeutic gain for heartburn. In a systematic 
literature review performed by Kahrilas et al. (56), sev-
en placebo-controlled trials were analyzed, and the rel-
Figure 9. Summary of PPI efficacy for the potential manifestations of 
GERD, as assessed in randomized controlled trials (57).
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Figure 8. The rate of the complete resolution of heartburn for 7 
consecutive days and heartburn-free days (%) during the 28-day 
observation period was significantly higher in the PPI+alginate 
combination group than in the PPI alone group (49).
ative therapeutic gain obtained with PPIs was only 17% 
for regurgitation, while it was >20% for heartburn. The 
therapeutic effects of PPIs are summarized in Figure 9, 
including a comparison of the efficacy of PPIs in treat-
ing esophagitis with their efficacy in treating other GERD 
syndromes (57) (Figure 9).
In a 24-hour intraesophageal impedance-pH moni-
toring study, Zerbib et al. (58) showed that there were 
more reflux events associated with regurgitation than 
with heartburn in PPI-refractory patients. These data 
support the idea that persistent regurgitation is a major 
cause of a lack of a complete response to PPI treatment. 
Alginic acid, a rafting anti-reflux agent, forms a foamy 
gel that floats on the surface of gastric contents when it 
interacts with gastric acid (32). Since it generates a bar-
rier-like gel that sits above the gastric contents, alginate 
theoretically has specific properties that can prevent 
regurgitation.
In support of these data, a randomized, double-blind, 
placebo-controlled clinical trial showed that there was 
a greater decrease in regurgitation symptoms in the al-
ginic and antacid combination group than in the placebo 
group (least-squares mean difference -0.62; p=0.0033) 
(59). Additionally, a multicenter study showed that an 
alginic acid and antacid combination was more effi-
cient in decreasing regurgitation events in GERD pa-
tients than a placebo (least-squares mean difference 
-0.28; p=0.029) (60). Lai et al. (38) showed that an al-
ginic acid and antacid combination was more efficient 
for decreasing regurgitation events in patients with 
NERD at the end of the 6 weeks of treatment than ant-
acid monotherapy (p=0.008). Chiu et al. (44) reported 
that the effect of alginic acid was comparable to that 
of omeprazole for decreasing regurgitation or heartburn 
frequency in patients with GERD. This study had some 
limitations. For example, patients who were diagnosed 
with NERD and heartburn or regurgitation (either one) 
as the main symptom (at least 2 days a week) were en-
rolled in this study. For these reasons, this study includ-
ed patients with only heartburn and patients who expe-
rienced symptoms more than 2 days a week (patients 
with severe GERD) (44) (Table 4).
In conclusion, PPIs are the mainstay of medical manage-
ment for GERD. Although PPIs provide relief from most 
symptoms, reflux may persist and alginates relieve regur-
gitation more effectively than placebo and antacids.
The role of alginates in the management of atypical 
gastroesophageal reflux disease symptoms
According to the Turkish Reflux Study Group Consensus 
Report, the established GERD-associated conditions in-
clude cough, laryngitis, asthma, dental erosion and chest 
pain (61) (Figure 10). GERD typically presents with esoph-
ageal symptoms such as heartburn and regurgitation 
(62); however, it may also present with extresophageal 
symptoms (63).
Figure 10. Classification of GERD (Turkish Reflux Study Group 
Consensus Report, 61).
Study  Study Protocol Control group ITT patients (n) Relief of regurgitation p
Thomas E, 2014(59) Pilot, randomized,  Placebo 110 Alginate was better 0.0137 
 double-blind,  
 placebo-controlled
Wilkinson J, 2019(60) Multicenter, randomized,  Placebo 424 Alginate was better 0.029 
 double-blind, 
 placebo-controlled
Lai IR, et al 2006(38) Prospective,  Antacid 121 Alginate was better 0.0006 
 randomized, and  
 active controlled
Chiu CT, et al 2013(44) Randomized Omeprazole 183 Same** 0.487
ITT: Intention-to-treat (ITT); ** Relief of heartburn or regurgitation.
Table 4. The results of studies on the efficacy of alginates in the reduction of regurgitation.
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Laryngopharyngeal reflux disease (LPR) is an extrae-
sophageal variant of GERD that refers to the retrograde 
flow of gastric contents to the larynx and pharynx. Ex-
tra-esophageal reflux symptoms in LPR may develop in 
two ways. Injury may occur via the exposure to the gastric 
acid, pepsin and bile salts in the laryngopharyngeal area 
in the “direct injury” or “reflux” theory. The other theory 
is the “reflex” theory. According to this theory, mucosal 
receptors are stimulated by reflux material, which then 
activate inflammatory mediators that cause extraesoph-
ageal symptoms such as a bronchial cough reflex or glo-
bus sensation (63).
In the Progression of Gastrointestinal Reflux Disease 
(ProGERD) study, Jaspersen et al. (64) reported that the 
extraesophageal symptom rate was 32.8%. The most 
common extraesophageal symptom was chest pain 
(14.5%), followed by chronic cough (13%). The extrae-
sophageal symptom rate was significantly higher in EE 
(34.9%) than in nonerosive esophagitis (30.5%).
Non-cardiac chest pain
PPIs are the therapy of choice for patients with non-car-
diac chest pain (NCCP) due to their high potency and 
effective acid inhibition. Reflux-related NCCP shows 
the highest response rate of the entire GERD spectrum 
(number-needed-to-treat (NNT)=1.7) (65). In a random-
ized, double-blind, placebo-controlled trial, the overall 
treatment response to omeprazole 20 mg twice daily for 
8 weeks was 81% and was superior to that of placebo in 
patients with GERD-related NCCP, as documented by 24-
hour esophageal pH testing (66). In a recent meta-analysis, 
Leiman et al. (33) showed that alginate was also capable of 
improving global GERD symptoms, including NCCP.
Cough
Cough is another extraesophageal symptom of GERD, 
and GERD is one of the three most common causes of 
chronic cough. In uncontrolled studies, PPIs were shown 
to improve symptoms; however, in a double-blind ran-
domized study, only 35% of patients responded to ome-
prazole (40 mg/day) treatment (67). Additionally, a me-
ta-analysis of placebo-controlled studies documented 
the ineffectiveness of PPI therapy for chronic cough (68). 
It should be noted that the uncertainty of the associa-
tion between chronic cough and GERD in these studies 
is most likely due to inappropriate patient selection be-
cause of the uncertainty of the diagnostic tests.
Adding alginic acid to PPI treatment has been shown to 
be effective for the resolution of chronic cough related to 
GERD. In a study by Lieder et al. (69) 15 patients received 
lansoprazole 15 mg twice daily and a 10-mL standard 
dose of Gaviscon Advance (Reckitt Benckiser, Kings-
ton-upon-Thames, UK) (containing Na alginate 1 g⁄10 
mL and potassium (K) HCO3 200 mg⁄10 mL) at bedtime 
for at least 2 months. Chronic cough was resolved in 93% 
(14/15) of patients (69).
Laryngopharyngeal reflux
The pathophysiology of LPR is suggested to be a result of 
two main mechanisms that are similar to those in cough. 
The first of these mechanisms is vagally mediated throat 
clearing and coughing responses causing physical laryn-
geal injury that results from the irritation of the distal 
esophagus by refluxed gastric contents. The other mech-
anism of laryngeal injury is direct contact with erosive 
gastric refluxate. Although PPIs are able to remove acid-
ic components of the gastric refluxate, they are unable 
to neutralize other more damaging gastric components, 
such as pepsin and bile acids (70).
PPIs are the standard therapy for patients with suspected 
LPR. In open-label studies, PPIs have been shown to be 
beneficial for decreasing LPR symptoms (71,72). How-
ever, there is growing evidence from randomized place-
bo-controlled trials that PPI treatment is not effective for 
the treatment of LPR. For instance, in contrast to these 
open-label uncontrolled studies, a placebo-controlled 
multicenter study showed that esomeprazole 40 mg 
(twice a day) was comparable to placebo in regard to the 
symptomatic response in suspected LPR patients (73). 
Similarly, in a more recent meta-analysis of controlled 
studies, PPI therapy was found to be ineffective for LPR 
(74).
Alginate, sometimes in combination with PPIs, has been 
indicated to be effective in the treatment of the symp-
toms of reflux as well as in the treatment for EER symp-
toms. Alginate produces a mechanical antireflux barrier 
above the gastric acid pocket. This barrier reduces the 
risk of further symptoms by preventing the reflux of 
gastric contents, including pepsin and bile salts, into the 
esophagus and aerodigestive area (75). In a study by Mc-
Glashan et al. (76) LPR patients who received a liquid algi-
nate suspension had significant improvements in symp-
tom scores and clinical findings compared to patients 
who received the control. In another study conducted 
by Tseng WH et al. (77), liquid alginate significantly im-
proved symptoms (decrease in the reflux symptom index 
(RSI) scores) and the number of reflux episodes with 24-
hour intraesophageal MII-pH monitoring when compared 
S119
Turk J  Gastroenterol  2019;  30(Suppl  2) :  S109-36 Bor et  a l .  Alginates in GERD
with baseline, but was not superior to placebo. Wilkie MD 
et al. (78) reported that alginate alone was comparable 
with alginate+PPI combination for decreasing RSI scores 
(p=0.75) in patients with LPR. The authors concluded 
that alginic acid monotherapy was capable of treating 
LPR and was a safe and low-cost empirical treatment.
In conclusion, PPI treatment is the standard of care for 
the diagnosis and therapy of patients suspected of hav-
ing extraesophageal GERD symptoms. However, the 
therapeutic effect of PPIs for extraesophageal symptoms 
is not satisfactory compared to that of typical GERD, 
and the treatment of the extraesophageal manifesta-
tions of GERD remains a challenge. According to these 
findings, alginate alone or in combination with PPIs may 
be useful for the relief of EER symptoms. Currently, be-
cause of the lack of objective diagnostic methodologies, 
it is difficult to come to a precise conclusion. There is a 
strong need for further studies in patients with these 
symptoms.
Long-term and/or on-demand use of alginates
Many patients receive long-term treatment following 4 to 
8 weeks of initial GERD treatment to maintain adequate 
symptom control (79). After the cessation of treatment, 
in up to 75% of patients, GERD symptoms rapidly reoc-
cur; therefore, the arranging of maintenance treatment is 
very important. Different maintenance treatment modal-
ities have been defined. According to the Turkish Reflux 
Study Group Consensus Report definitions, there are 3 
types of maintenance treatments. These are continu-
ous treatment, intermittent treatment and on-demand 
treatment. In continuous treatment, patients continue to 
take their drugs without stopping therapy. In on-demand 
treatment, patients take their drugs at a standard or 
maintenance dosage when their symptoms occur. Finally, 
in intermittent treatment, patients receive a standard or 
maintenance dose of a drug for two to eight weeks when 
their symptoms recur (80).
Although randomized, controlled studies have demon-
strated that the most effective drugs for the maintenance 
treatment of GERD are PPIs, the safety of these medica-
tions for long-term use has raised many questions (81). A 
recent expert review reported by the American Gastro-
enterology Association advised the periodic re-evaluation 
of the PPI dosage to detect the lowest effective dose for 
maintenance treatment (82). In addition to safety issues, 
a significant proportion of patients with GERD (25-47%) 
exhibit poor or moderate compliance for their prescribed 
PPIs (83,84). Due to the abovementioned issues, potent, 
cost-effective and safe long-term maintenance strate-
gies are necessary for some GERD patients.
In symptomatic GERD, preventing acidic flow into the 
esophagus is an alternative medical treatment. By cre-
ating a barrier to gastroesophageal acid exposure, alginic 
acid seems to be a useful alternative medical treatment 
for symptomatic reflux disease. Several randomized 
studies have demonstrated that alginate was superi-
or to placebo or antacids for decreasing GERD symp-
toms. Alginate was found to be superior to a placebo or 
an antacid (OR: 4.42 (95% CI: 2.45-7.97)) in a recent 
meta-analysis. Additionally, the efficacy of alginate was 
comparable to that of omeprazole or H2 receptor block-
ers for symptomatic GERD (OR: 0.58; 95% CI 0.27-1.22) 
(33). In a more recent study, Wilkison et al. (60) showed 
that patients receiving alginic acid had significantly high-
er treatment effects (evaluated with the Reflux Disease 
Questionnaire) for GERD symptoms than patients taking 
a placebo (p<0.001). All of these studies were short-term 
studies and showed that in the short-term symptomatic 
treatment of patients with NERD, alginates are superior 
to antacids and placebos and were as effective as ome-
prazole and H2RAs. However, there are no studies in the 
literature analyzing the efficacy of alginates for mainte-
nance therapy in GERD.
There are limited data on whether continuous treatment 
improves the quality of life and symptomatic recovery. 
Additionally, continuous treatment, especially with PPIs, 
raises concerns regarding safety and cost-effectiveness 
(80). Intermittent or on-demand therapy following symp-
tomatic resolution after induction therapy seems to be 
more reasonable for patients with NERD or EE LA grade 
A and B disease. The purpose of on-demand treatment 
is the quick relief of symptoms using fast-acting drugs. 
To achieve this goal, alginates are theoretically a good 
alternative to PPIs for on-demand treatment. Because it 
takes hours to raise the intragastric pH above 4 after the 
first dose of PPIs (85), the time interval to symptom relief 
is shorter with alginates. When added to simulated gas-
tric acid (e.g., 0.1 N HCl) alginate forms a floating raft-like 
structure within a few seconds. In an in vitro study, Wash-
ington et al showed that a liquid alginic acid formulation 
(500 mg Na alginate, 267 mg NaHCO3 in 10 mL; Reckitt 
& Colman, UK) rapidly elevated the pH of the acid phase 
from 2.0 to 5.6 (86). In support of these data, in an in vivo 
study, Dettmar et al. (35) analyzed the time of onset of 
the effect of alginate, omeprazole, ranitidine and control 
based on the esophageal and intragastric pH and found 
that alginate achieved a significantly more rapid reduc-
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tion in acid exposure in the esophagus than either raniti-
dine or omeprazole.
Studies have been performed in vitro regarding pregnan-
cy and GERD that showed that the effect is fast and that 
alginates can be used in on-demand therapy. However, 
comparative studies do not exist in this particular group.
In conclusion, alginates can be recommended for the 
maintenance treatment of patients with NERD or EE LA 
grade A and B disease as an on-demand therapy.
The role of alginates in the step-down or cessation of 
PPIs
The recurrence rate of typical symptoms within six 
months reaches approximately 80% after the cessation 
of PPIs. There are two different therapeutic approaches 
to treating GERD in clinical practice. In the step-up ap-
proach, treatment begins with lifestyle modifications, 
antacids alginates and H2RAs. In step-down therapy, 
in contrast to the step-up approach, patients receive a 
PPI in the beginning of treatment, and subsequently, the 
treatment is stepped down to identify a regimen that al-
lows the patient to be symptom-free (87). In the step-up 
approach, treatment begins with the most cost-effective 
strategy and the more potent, more expensive medica-
tions are used if the initial therapy fails. However, in step-
down therapy, less expensive medications are used only 
after symptom relief has been achieved with PPIs (88,89).
There are two different studies in the literature com-
paring the efficacy of step-up and step-down therapies, 
which showed that the step-down approach was more 
effective than the step-up approach for relieving symp-
toms and resolving esophagitis in patients with GERD 
(87,90). However, after an initial treatment with a PPI, 
the recurrence of GERD symptoms occurs in the majority 
of the patients who are stepped down to an H2RA, and 
these patients need a PPI, especially those who have se-
vere GERD (3,4). In mild or moderate GERD, it has been 
suggested in several reports that the tapering or cessa-
tion of PPI treatment is possible (91,92).
Observational studies have documented that long-term, 
especially high-dose PPI treatment, may cause some ad-
verse events, including an increased risk for hip and spine 
fractures, bacterial overgrowth, Clostridium difficile coli-
tis, and community-acquired pneumonia. Additionally, 
long-term PPI treatment is associated with high pharma-
cy costs (93), but it should be noted that the pharma-
coeconomics might be different in developing or under-
developed countries. For patients with mild-to-moderate 
GERD who become symptom-free with PPI therapy, an 
appropriate step-down treatment approach consisting of 
the tapering or cessation of PPIs is essential in the long-
term period.
In a recent report, it was asserted that prescribing non-
PPI medications for patients with GERD may facilitate 
tapering or discontinuing PPI therapy. In the same report, 
it was implied that alginate seemed to be an attractive 
alternative treatment to keep patients asymptomatic 
during tapering or after the cessation of a PPI. The au-
thors came to this conclusion since alginate has limited 
systemic absorption, creates a raft-like protective barrier 
to limit reflux and neutralizes the acid pocket after a meal 
(94). In support of this statement, a recent position paper 
from the Romanian Society of Neurogastroenterology 
reported that an alginate-antacid combination was su-
perior to both placebos and antacids to treat mild reflux 
symptoms and could be used to treat persistent reflux 
symptoms with a PPI therapy (95). In the only study con-
cerning the efficacy of alginate in stepping down from or 
off of PPIs, Murie et al. (96) showed that among patients 
taking an alginate suspension during the step-down/ces-
sation of therapy, 83% of these patients successfully re-
duced or stopped their PPIs at the end of 1 year.
In conclusion, although there are limited data in the liter-
ature showing the role of alginate in the step down/ces-
sation of PPIs for GERD treatment, in mild-to-moderate 
GERD, alginate seems to theoretically be an appropriate 
therapy for preventing symptom relapse during the PPI 
tapering and off-PPI period. We suggest the following ap-
proaches for tapering or stopping PPIs:
• Fully stop PPIs and observe patients with mild symp-
toms
• Taper the dose and stop
• Switch to intermittent or on-demand use with PPIs 
and/or alginate
• Decrease to the lowest effective dose and continue
• Stop and continue with alginate, with either continu-
ous or on-demand treatment with alginate or anoth-
er non-PPI agent
Alginates in the treatment of gastroesophageal reflux 
in children
Introduction
Gastroesophageal reflux (GER) in children is defined as 
the passage of gastric contents into the esophagus with 
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or without regurgitation and/or vomiting. When GER leads 
to troublesome symptoms and/or complications, such as 
esophagitis or stricture, it is considered pathologic and is 
referred to as GERD. In clinical practice, the differentia-
tion of these two clinical conditions may be difficult, and 
there is currently no standard diagnostic tool for the di-
agnosis of GERD in infants and children (97).
Regurgitation (“spitting up”) and GER are common in 
infants. Half of healthy infants from birth to 3 months 
old have regurgitation. Regurgitation peaks at 67% at 4 
months of age and disappears in 95% of infants by 12 
months of age (98). Although regurgitation is physiologic 
and healthy infants spontaneously recover, almost 25% 
of parents are concerned about this condition and seek 
medical care.
Pharmacological therapy is not indicated for children with 
GER without complications and is mostly reserved for 
children diagnosed with GERD. The optimal therapy for 
GERD is not known (97). The differences in the definition 
of GERD, the measures and reported outcomes among 
studies are another problem (99). With regard to Na al-
ginate studies, differences are more common among the 
studies. In addition to the differences between the inclu-
sion criteria and follow-up, the content of the prepara-
tions, dosages, the time of administration, and the defini-
tion of response to treatment also differ.
In alginate preparations, Na alginate may be used alone or 
together with magnesium (Mg) alginate and/or mannitol 
and/or NaHCO3/KHCO3 and/or CaCO3. In some formula-
tions, Mg alginate is present without Na alginate. Alginate 
preparations without HCO3 prevent reflux by increasing 
the viscosity of gastric contents, whereas in the presence 
of HCO3, alginate preparations neutralize gastric acid and 
form a “foam raft” in the presence of gastric acid that 
floats on top of the gastric contents and prevents reflux. 
Aluminum (Al) has been removed from alginate prepara-
tions because of the side effects (26,37,100).
Although the North American and European Societies 
for Pediatric Gastroenterology, Hepatology and Nutrition 
(NASPGHAN and ESPGHAN, respectively) do not recom-
mend the use of alginate because of the limited evidence 
for its efficacy in children (97), in the recently published 
National Institute for Health and Care Excellence (NICE) 
guidelines, alginates are recommended as an alternative 
treatment to feed-thickening agents in breastfed in-
fants or as a trial in infants for whom symptoms persist 
despite conservative measures (101). Additionally, a re-
cent Cochrane review stated that there is weak evidence 
suggesting that Gaviscon Infant improves symptoms in 
infants, including those with functional reflux (100).
Table 5 summarizes the results of the studies with algi-
nates in children.
Studies with alginate formulations
a. Alginate studies without a control group
Weldon and Robinson (102) first reported the use of 
Gaviscon to manage infants ranging in age from 2 weeks 
to 11 months with uncomplicated GER in 1972. In this 
open-label prospective study, 18 infants with regurgita-
tion and vomiting received Gaviscon powder (contain-
ing alginate, Mg trisilicate, Al hydroxide gel and NaHCO3) 
at a dose of ½ to 1 tsp with a 120-mL feed. All of the 
infants had a good symptomatic response to the treat-
ment. The limitations of the study were the absence of 
the objective diagnosis of GERD and statistical results. 
In 1987, Gaviscon (combined with antacids, 3-5 mL af-
ter meals) was tested as a component of a triple-therapy 
(milk-thickening agents plus domperidone (0.8-1.0 mg/
kg/day in three divided doses)) was tested on 24 infants, 
all with abnormal pH recording results, who were nonre-
sponders to milk-thickening agents and positional ther-
apy (103). The age range was 4-12 weeks at the begin-
ning of the study, and triple-therapy was administered 3 
to 5 weeks after the beginning of the study. After 10-14 
days of therapy, pH monitoring was performed. The clin-
ical symptoms of GERD disappeared in 15 of the infants, 
improved in 8, and remained unchanged in 1 infant with 
a hiatal hernia. pH monitoring showed an improvement 
in 7 infants and a complete normalization in 17 infants. 
Unfortunately, it was impossible to determine which part 
of the triple-therapy was (more) effective in this study.
Le Luyer et al. (104) evaluated the efficacy and safety of 
alginic acid (Gaviscon suspension; Na alginate, sodium hy-
droxide (NaOH) and CaCO3) at two different doses (1 to 
2 mL/kg/day in divided doses after meals) in 76 children 
with GERD, as confirmed by pH monitoring. Irrespec-
tive of the dosage used, the frequency of regurgitation 
(p<0.00001) and vomiting (p=0.01) decreased signifi-
cantly after four weeks of treatment. The tolerance was 
good, and no adverse effects were reported. This study 
showed the improvement of clinical symptoms in chil-
dren with GERD who were diagnosed by pH monitoring. It 
is an open question whether the use of a hydroxide-con-
taining preparation may have had an additional benefi-
cial effect on reflux symptoms. Le Luyer et al. (105) con-
S122
Bor et  a l .  Alginates in GERD Turk J  Gastroenterol  2019;  30(Suppl  2) :  S109-36
Ref# Methods  Population Test agent(s) and doses Interventions Outcomes/results Comments
Studies without control group
102  Open-label  18 infants (age  Gaviscon powder Clinical Vomiting resolved or No objective diagnosis of 
 prospective  range 2 weeks to (alginate, Mg trisilicate, observation reduced in all patients GERD. No statistical 
 study 11 months) with  Al(OH)3, NaHCO3) ½-1   analysis 
  regurgitation and  tsp with 120 mL feed 
  vomiting    
103 Open-label  24 infants Gaviscon (combined Repeat pHM Clinical symptoms It was impossible to decide 
 prospective  (age range 4-12 with antacids (3-5 mL)  after 10-14 disappeared in 15 infants, which part of the triple- 
 study weeks) with  after meals) as  days of improved in 8 infants, and therapy was effective in 
  abnormal pHM  a component of a therapy remained unchanged in 1 this study 
  results.  triple-therapy (milk-  infant with a hiatal hernia.  
  Nonresponders  thickening agents plus  pHM showed an 
  to milk-  domperidone-  improvement in 7 infants 
  thickening  0.8-1.0 mg/kg/day in  and a complete 
  agents and  three divided doses)  normalization in 
  positional    17 infants 
  therapy after  
  3-5 weeks    
104 Open-label,  76 infants, GER Gaviscon suspension Clinical Both doses of Gaviscon A total of 18/69 patients 
 multicenter  confirmed (Na alginate, NaOH, observation significantly and equally who underwent endoscopy 
 study  by pHM CaCO3) 1 or 2   reduced regurgitation had erythematous and 5 
   mL/kg/day, divided into   (p<0.00001) and vomiting had EE. What was the 
   doses after meals   (p=0.01), were well effect of NaOH as an 
   for 4 weeks   tolerated and caused no  antacid? 
     adverse effects 
105 Open-label  83 children with Na alginate 5 mL, 3 3-hour The RI, total number of Very short duration. 
 prospective  symptomatic hours after a meal postprandial reflux episodes, and Na alginate was 
 study GER (48 males,   pHM followed mean duration of reflux administered 3 hours after 
  mean age 7   by the 2nd 3- episodes reduced the meal, was different 
  months, range 15   hour pHM significantly (p<0.00001) from what is 
  days to 57   after the  recommended. 
  months). All had   intake of Na 
  abnormal 3-hour   alginate 
  postprandial  
  readings by pHM  
  (RI>4.2%)    
106 Open-label 28 infants  Gaviscon 0.5 A second Total number of refluxes, - 
  (age range 3 to  mL/kg/dose four times pHM after 2 number of refluxes longer 
  12 months) with  a day, 20 minutes months of than 5 minutes and RI 
  GER diagnosed  after meals treatment significantly improved 
  by 24-hour pHM   after treatment (p<0.05)
107 Prospective,  43 infants Mg (plus simethicone, 48-h MII-pHM The median number of all Three patients were 
 observational  (median age 68  NaHCO3 and fructose) (24 hours MII reflux (acid and excluded because of MII- 
 case-control  days, range or Na alginate (plus without non-acid) episodes was pH tracing artifacts. 
 study 25-306) with  NaHCO3 and CaCO3), medication reduced (p<0.001). Potential to adapt to the 
  GER symptoms  1 mL/kg/day, divided followed by Proximal GER episodes presence of the probe 
  who were  over the number of the second decreased (p=0.007). during the second period 
  unresponsive to  meals, administered 24 hours with Crying-fussiness of MII-pHM. 
  behavioral and  after each feeding Mg or Na (p=00012), cough There was no long-term 
  dietetic   alginate (p=0.005) and follow-up 
  modifications.   regurgitation episodes 
  MII-pHM; RI ≥7%    (p=0.04) improved. 
  and the presence    No difference between 
  of >100 MII    Na and Mg alginate 
  episodes/day were 
  considered  
  pathologic     
Table 5. Studies with alginates in children.
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Ref# Methods  Population Test agent(s) and doses Interventions Outcomes/results Comments
Studies compared with placebo and/or other medications
108 DB, RC, 3- 30 children aged Alginate + antacid 48-hour pHM, No significant difference No data on adverse 
 armed trial 4 months to  (10 mL for infants, the first 24 among the 3 groups with effects. Exact preparation 
  17 years. 20 mL for older hours without regard to the frequency of the alginate-antacid 
  No difference in  patients) vs medication of regurgitation episodes was not discussed. P 
  demographic,  metoclopramide and the (episode defined as values were not reported 
  clinical  0.17 mg/kg tid second 24 pH <4), over 24 hours and 
  characteristics and  (24-hour period) vs hours with the total duration of acid 
  baseline pHM  placebo (saline 0.9%, medication/ reflux (minutes) 
  measures 1 mL every 8 hours) placebo   
109 DB, RC trial 20 children (mean  Gaviscon Infant (with pH monitoring Total number of reflux Difference between mean 
  age 28 months,  NaHCO3, 2 g) vs at baseline episodes, reflux episodes ages: Gaviscon (21 
  range 2 to 84  placebo (lactose, 2 g) in and on day 8 more than 5 minutes, RI, months) vs placebo (35 
  months).  240 mL milk for 8 days  mean duration of reflux months). Short duration (8 
  None of the    during sleep, the number days). High amount of 
  children who    of reflux episodes 2-hours lactose (up to 12 g/day). 
  underwent an    postcibally significantly Adverse effects not 
  endoscopy had    decreased in the reported 
  evidence of    Gaviscon group.  
  esophagitis    No change in the  
     placebo group 
110 Open-label,  49 children Gaviscon tablet Clinical Famotidine was superior At repeat endoscopy, 
 parallel- (34 males) aged (Na alginate, Al(OH)3, observation. to Gaviscon for esophagitis was resolved in 
 design 2-16 years,  Mg trisilicate) Repeat symptomatic relief 43.4% of patients with 
  endoscopically  (24 children) vs endoscopy and the resolution alginate and in 41.6% of 
  documented  famotidine  of esophagitis patients in the famotidine 
  reflux esophagitis (25 children).   group (p>0.05); however, 
   1 Gaviscon tablet after    the improvement of the 
   meals and before    endoscopic grades induced 
   bedtime or 1 mg/kg    by famotidine was 
   famotidine.   significantly greater 
   6 months duration   
111 Randomized  50 infants (aged Gaviscon Infant (1/2 Diary scores, Severity score significantly Cisapride is no longer 
 parallel group 2–18 months), all  sachet in 90 mL feed+ parental improved in both groups available because of 
  bottle-fed and  carobel) vs cisapride evaluation and but the difference was adverse effects 
  had GER proven  (0.2 mg/kg/dose x4), repeat phM p>0.05. Parents’ 
  on pHM (RI ≥5%)  1 month  after 1 month consideration was 53%  
     better in the cisapride  
     group and 79% in the  
     Gaviscon+carobel group  
     (p=0.055). pH study: no  
     significant difference  
     among groups 
112 DB, RC trial 80 children (aged  Mg(OH)2-Al(OH)3+ Clinical Symptoms/pH probe: Short-term study in young 
  1–18 months;  domperidon (group A) observation. group A was superior to children. All children 
  median 4.5  vs Gaviscon Infant Repeat pHM groups B, C, and D. pHM received a thickening 
  months) with GER  (with Al)+domperidon  variables were better in agent 
  but no erosions  (group B) vs domperidon  group A than in the other 
  were observed on  (group C) vs placebo  3 groups. The total reflux 
  endoscopy.  (group D) for 8 weeks  time in groups B, C, and D 
  Diagnosis: clinical,    were not significantly 
  radiological and    different after treatment 
  pHM (RI>5.2%).  
  Patients were  
  stratified by age 
  (<12 months, >12  
  months) and RI  
  (<10%, >10%)       
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Ref# Methods  Population Test agent(s) and doses Interventions Outcomes/results Comments
113 RC trial 36 children  Alginate alone Patients Although a significant Alginate plus lansoprazole 
  (median age 5.6  (2 mL/kg/day in divided underwent a improvement in symptoms is more effective than 
  years, range 12  doses), lansoprazole 24-hour pHM was noted, 24-hour pHM alginate or lansoprazole 
  months to 12  1.5 mg/kg twice daily at one week, and endoscopy (p<0.01) alone 
  years) with a  before meals or symptomatic in the patients with EE 
  diagnosis of  lansoprazole + alginate evaluation at given alginate alone and 
  GERD based on  with the same doses four weeks alginate and lansoprazole 
  symptoms,  as above and symptom combination achieved 
  24-hour pHM   assessment significantly better 
  and endoscopy  with endoscopy  symptom improvement 
    at eight weeks than those in the other  
     two groups (p<0.01).  
     The improvement in the  
     RI in the alginate and  
     lansoprazole group was  
     significantly superior to  
     that in the other two  
     groups (p <0.05) 
114 DB, RC trial,  20 bottle-fed Gaviscon Infant (Na/Mg 24-hour MII- No difference regarding No discussion of the group 
 crossover  infants (mean age alginate, no HCO3, 625 pHM (dual- the median number of demographics (age/sex) or 
 design  164 days, range  mg in 225 mL milk) vs channel) reflux events per hour how the infants were 
  34-319 days),  placebo (mannitol+ during which (p=0.78), median number recruited. Symptoms/ 
  with symptoms  solvito, 625 mg in 225 there were 6 of acid reflux events an histology not recorded. 
  clinically  mL milk) (3+3) random hour (p=0.94), minimum Many reflux episodes 
  suggestive   administrations distal (p=0.41) or were diagnosed based on 
  of GERD    of study drugs  proximal (p=0.23) pH,  impedance not on a pH 
     total acid clearance time  probe. Short-term study, 
     per hour (p=0.32), total small numbers. A volume 
     reflux duration per hour  of 225 mL of milk per 
     (p=0.096), and marginally  feeding is not possible for 
     lower reflux height in the  a 34-day-old baby. No 
     esophagus with Gaviscon  information about night/ 
     Infant (p<0.001) day distribution
116 Phase III, RC,  90 infants aged 0 Gaviscon Infant Infants Reduction in the number Duration of the study 
 ITT, parallel- to 12 months (Al-free, Na and Mg reassessed and severity of vomiting was 14 days. Total daily 
 group  attending 25 alginate, 225 and 87.5 after 7 and episodes (p=0.009) in the doses were unclear. Four 
 multicenter  general practices. mgs in each sachet, 14 days previous 24 hours. infants from the Gaviscon 
 study Clinical diagnosis respectively; weight-  Number of symptom-free Infant group and 4 infants 
   adjusted dose, after   days (at least 10% from the placebo group 
   meals in a volume of   symptom-free days) were withdrawn due to 
   5-10 mL) vs placebo   (p = 0.027) Improvement adverse effects. Five 
      in symptoms in patients  children were withdrawn 
     on Gaviscon Infant  for a lack of efficacy 
     (investigators: p=0.008,  (Gaviscon Infant 2, 
     parents: 0.002) placebo 3). Compliance  
      71% Gaviscon Infant,  
      59% placebo
117 RC trial 75 patients (age  Group A (n: 25), Mg I-GREQ after After 1 month, group A High dropout rate. 
  range 1-10  alginate + simethicone; 1 and 2 had a significant Absence of an objective 
  months) with  group B (n: 25), rice- months improvement in symptoms. diagnostic test. The 
  reflux and  starch-thickened  After 2 months, all 3 groups amount of rice starch was 
  vomiting, 64  formula; and group C  of patients showed a high 
  patients  (n: 25), control-  significant reduction in  
  completed reassurance   symptom scores.  
     Decrease in median  
     symptom scores; group A  
     vs B p<0.002, A vs  
     C <0.0001, B vs C <0.001) 
Table 5. Studies with alginates in children. (continued)
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ducted another study in 1990. In that study, 83 children 
with symptomatic GERD (48 males, mean age 7 months, 
range 15 days to 57 months) were assessed by pH mon-
itoring. All patients showed acidic pathological GER on 
the 3-hour postprandial esophageal pH monitoring (the 
percentage of the time during which pH <4 “reflux index 
(RI)” >4.2%), and all had a second measurement within 
the following 3 hours after the intake of a single (5 mL) 
dose of Na alginate. The RI, the total number of reflux 
episodes, and the mean duration of reflux episodes were 
significantly reduced (p<0.00001). The limitations of this 
study were the very short duration and the administration 
of Gaviscon 3 hours after a meal. Most reflux episodes 
occur within 2 hours postprandially, and Gaviscon is most 
effective when it is administered 30 minutes after a meal.
Maestri (106) evaluated the effect of Na alginate (Gavis-
con) in 28 children diagnosed by 24-hour pH monitoring. 
After the first pH recording, all patients were adminis-
tered Gaviscon (0.5 mL/kg/dose four times a day, 20 min-
utes after meals). After 2 months of treatment, pH was 
monitored a second time. The total number of refluxes, 
the number of refluxes longer than 5 minutes and the RI 
significantly improved after treatment (p<0.05).
In a prospective, observational study, Salvatore et al. (107) 
enrolled 43 infants (median age 68 days, range 25-306) 
who were referred for MII-pHM because of persistent 
GERD symptoms that were not responsive to behavioral 
and dietetic modifications. All infants underwent a 48-
hour MII-pHM; a baseline recording was obtained during 
the first 24 hours, while Mg (Mg alginate, simethicone, 
NaHCO3, and fructose) or Na alginate (Na alginate, NaH-
CO3, and CaCO3) (both preparations were administered 
1 mL/kg/day, divided over the number of feeds) was ad-
ministered during the second 24 hours. Three patients 
were excluded because of MII-pH tracing artifacts. The 
median number of all MII reflux episodes (p<0.001), acid 
Ref# Methods  Population Test agent(s) and doses Interventions Outcomes/results Comments
Studies in newborns/preterm infants 
119 Open-label 34 preterm  4 x 1 mL Na alginate pHM at A total of 79.4% The duration was short. 
  (postnatal ≥7 days,  with KHCO3 baseline and responded to treatment. No control group 
  only breast milk).   after 48 hours Significant improvement 
  Clinical symptoms    in the number of reflux 
  and pHM (RI>5%)    episodes, the number of 
  diagnosed   reflux episodes >5  
     minutes, the duration of  
     the longest reflux episode  
     and RI. Decrease in  
     vomiting and improvement 
     in weight gain 
120 Open-label Thirty-two  Na alginate Twenty-four- Na alginate significantly No data on reflux 
  preterm infants  (0.25 mL/kg/dose) hour pHM decreased the number of symptoms. Short duration 
  with GER  4 times at alternating  acid GER events and the 
  symptoms meals during   acid esophageal exposure, 
   24-hour pHM  without any influence on  
     non-acid GER. Decreased  
     the number of GERs  
     reaching the proximal  
     esophagus 
121 Open-label Twenty-eight  Na alginate Six-hour (3+3) No decrease in apnea When alginate was given 
  preterm infants  (0.25 mL/kg with recording of frequency, acid GERs and during the first 3 hours of 
  with apnea,  NaHCO3) randomly MII-pH + acid exposure significantly recording, its effect may 
  postnatal age  given once during polysomno- decreased but not for continue during the 
  median 35 weeks  MII-pHM graphy non-acid GER indexes. second 3 hours of 
  (range 32-42    The drug reduced the  recording 
  weeks), on full    number of GER episodes 
  enteral feeding    reaching the proximal  
     esophagus  
Al(OH)3: aluminum hydroxide; NaHCO3: sodium bicarbonate; NaOH, sodium hydroxide; CaCO3: calcium carbonate; Mg(OH)2: magnesium hydroxide; GER(D): 
gastroesophageal reflux (disease); pHM: pH monitoring; MII: multichannel intraluminal impedance; DB: double-blind; RC: randomized controlled; ITT; 
intention-to-treat.
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(p<0.04), non-acid (p<0.004), proximal GER episodes 
(p<0.007) and the bolus exposure index (p=0.002) sig-
nificantly improved during alginate administration, with-
out a significant difference between Mg and Na alginate. 
Crying/fussiness (p=0.00012), cough (p=0.005) and re-
gurgitation (p=0.04) episodes all significantly improved 
during alginate administration. The study design by 
Forbes et al. (108) reduced possible confounding factors, 
such as feeding and awake/asleep periods. However, the 
infant may become adapted to the presence of the probe 
during the second 24-hour period, causing a normalizing 
effect. The clinical relevance of these differences needs 
to be ascertained because of the absence of long-term 
follow-up. This study also showed that Mg and Na algi-
nate have the same effect profile.
Although there were no control groups and different for-
mulations, dosages and designs were used, these studies 
showed that alginates may improve the clinical symp-
toms of GERD, such as regurgitation, vomiting, crying and 
fussiness and may improve the pH monitoring and/or MII-
pHM parameters.
b. Comparison of alginate-based formulations with pla-
cebos and/or other medications
In 1986, Forbes et al. (108) compared Gaviscon Infant 
liquid (antacid+alginate) with metoclopramide (0.5 mg/
kg/day in 3 doses before meals, 10 children, mean age 68 
months, range six to 168) and placebo (0.9% saline, 1 mL 
oral every 8 hours before meals, 10 children, mean age 65 
months, range four to 203) in a double-blind randomized 
trial. Ten children (mean age 68 months, range four to 
168 months) were given Gaviscon Infant every six hours 
(10 mL for infants and 20 mL for older children). Two 
24-hour pH recordings were made: at baseline and with 
treatment. There was no statistically significant differ-
ence among the three groups in regard to the number of 
episodes of GER or the total duration of GER during the 
initial 24-hour period of pH monitoring. Neither meto-
clopramide nor alginic acid with antacids decreased the 
number of the episodes of GER or the total duration of 
GER during the second 24-hour period of pH monitoring 
compared to placebo. The study design reduced possible 
confounding factors, such as feeding and awake/asleep 
periods. However, as the authors stated, an adaptation of 
the infant to the presence of the probe during the second 
24-hour period may have had a normalizing effect. The 
clinical relevance of these differences need to be ascer-
tained because of the absence of follow-up. The wide age 
range (4-203 months), the administration time of Gavis-
con (it was not stated if Gaviscon was given before or 
after each meal) and the presence antacid with alginate 
were the other limitations of this study.
In 1987, Buts et al. (109) obtained results that markedly 
contrasted with Forbes et al. (108) study. These research-
ers randomly assigned 20 infants and children with GER to 
two groups: the Gaviscon group (10 children, mean age 21 
months, range two to 84 months, 2 g alginate with NaH-
CO3 dissolved in 240 mL milk or in ½ a glass of water after 
each meal) and the placebo group (2 g lactose sachet after 
each meal) (10 children, mean age 35 months, range two 
to 144 months). Twenty-four-hour pH monitoring was 
performed at baseline and on day 8, and the symptoms, 
which included vomiting and the number of regurgitation 
episodes within 24 hours, were recorded by the staff. The 
patients were fed every 4 hours, alternating cow’s milk 
formula or orange juice (pH=4) during pH monitoring, and 
during the second pH recording, one sachet was given 
with each serving of milk or orange juice (six times/day). 
Before the trial, the pH monitoring variables (the Euler-By-
rne index, RI, mean duration and percentage of reflux time 
during sleep, total number of reflux episodes, number of 
reflux episodes longer than 5 minutes per 24 hours and 
number of reflux episodes per 2-hour postcibal periods) 
were abnormal in all the patients tested. An esophago-
gram was performed on all patients and revealed GER in 
13 patients. No evidence of esophagitis was observed at 
endoscopic examination in the 14 patients tested. The 
number of episodes of regurgitation per day reported by 
the parents reduced by three to four times during the trial, 
and vomiting improved in all cases, whereas no clinical im-
provement was observed in the placebo group. After eight 
days of treatment with Gaviscon, all the pH monitoring 
variables significantly (p<0.05) reduced by between 35% 
and 61% compared to the initial recorded values. In the 
placebo group, the changes were very small and were not 
significant (-9.5 to +8.2% of the initial values). The limita-
tions of this study were the wide age range, the high dose 
of lactose as a placebo and the frequent feeding protocol. 
Although statistical results were not reported, the age of 
the patients in the Gaviscon group was lower than that in 
the placebo group. Another problem with this study was 
the high dose of lactose that was used as a placebo. The 
authors did not state that the dose was regulated accord-
ing the age/weight of the patient and stated that the pa-
tients received 2 g of lactose every 4 hours. This means 
that a 2-month-old infant received 12 g of lactose (more 
than 2 g/kg/day) per day. This may have affected the re-
sults. The feeding frequency may have been another lim-
itation. The oldest patient in the study was 12 years old, 
and the patients were fed every 4 hours.
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In 1990 (110), alginate (0.5 g alginate) +antacid (0.1 g 
Al hydroxide, 0.025 g Mg trisilicate and 0.17 g NaHCO3) 
(group A; 1 tablet to be chewed 30 minutes after each 
meal and at bedtime) was compared with famotidine 
(group B: 1 mg/kg before supper at 7 pm) for the treat-
ment of endoscopically documented peptic esophagitis 
associated with acid reflux. Twenty-four of the 49 chil-
dren (mean age 9 years, 34 males) were randomly allo-
cated to group A, and 25 were allocated to group B. After 
6 months of treatment, endoscopy was repeated. Symp-
toms disappeared in 43.4% of children and improved in 
47.8% of children in group A and disappeared in 91.6% of 
those in group B (p<0.05). After six months, at endosco-
py, esophagitis had resolved in 43.4% of group A and in 
41.6% of group B, and the difference between these two 
groups was not significant; however, the improvement 
of endoscopic grades induced by famotidine was signifi-
cantly better than that of the other treatment (p<0.05). 
Histologic examination showed healed peptic esophagitis 
in 52.2% of the children in group A and in 70.8% of group 
B (p<0.001). No toxicity was observed with either treat-
ment. The authors concluded that famotidine is superior 
to alginate-antacid in treating peptic esophagitis associ-
ated with acid reflux since it induced a better symptom-
atic response and a greater improvement of endoscopic 
lesions.
Greally et al. (111) compared the efficacy of Gaviscon 
(containing HCO3, half a sachet in each 90 mL feed, 24 
infants) plus carobel carob seed flour (1-2 scoops in each 
90 mL feed) with that of cisapride (0.2 mg/kg/dose four 
times a day, 26 infants) in the treatment of GER in 50 
bottle-fed infants (age range 2 and 18 months) with con-
firmed GER by esophageal pH monitoring (RI ≥5%) in a 
randomized, parallel-group study. Parental evaluations, 
diary scores for the severity of symptoms, and 24-hour 
pH recordings before and after one month of treatment 
were compared. The diary scores significantly improved 
in both groups, and the median change was greater in 
the Gaviscon plus carobel group (p<0.05 and <0.01, re-
spectively), but the difference between the groups was 
not significant. In the cisapride group, 53% of the pa-
tients were considered better by their parents, while 
this ratio was 79% in the Gaviscon plus carobel group 
(p=0.055). With regard to the pH recording variables, five 
of 17 variables analyzed were significantly improved from 
the baseline in the cisapride group compared with 11/17 
variables in the Gaviscon plus carobel group, but a direct 
comparison between the two groups of changes in each 
pH variable revealed no significant differences (p>0.05). 
In 1994, Carroccio et al. (112) compared combinations 
of domperidone, Maalox (Mg hydroxide/Al hydroxide) 
and Gaviscon Infant (with Al) in 80 infants (median 4.5 
months; range one to 18 months of age) with the symp-
toms of reflux. Fifty of the infants had vomiting, 20 had 
weight loss, four had recurrent bronchopneumonia, five 
had prolonged crying after feeding and one had apnea. 
The diagnosis of GER was confirmed on the basis of ra-
diologic (at least two reflux episodes during fluorosco-
py) and 24-hour pH monitoring data (RI >5.2%). Before 
treatment, all patients underwent upper GI endoscopy. 
The patients were randomly divided into 4 groups (strat-
ified block randomization; age less/more than 12 months 
and total reflux time </> 10%): group A, domperidone 
(0.3 mg/kg/dose) 15 minutes before meals + Maalox (41 
g/1.73 mg/day) 1-hour and 3-hours after meals; group B, 
domperidone (0.3 mg/kg/dose) + Gaviscon Infant (0.7 
mL/kg/dose, immediately after and 3-hours after meals); 
group C, domperidone (0.3 mg/kg/dose) only; and group 
D: placebo 1-hour and 3-hours after meals. All children 
receiving formula had their feeds with thickener (1% 
Medigel). The demographic and clinical characteristics 
of the groups were not different. All children were clin-
ically evaluated and had 24-hour pH monitoring before 
and eight weeks after treatment. After treatment, the 
complete resolution of symptoms was higher in group A 
than in group B (p<0.018), group C (p<0.034), and group 
D (p<0.001). Although there was a statistically significant 
improvement in several pH monitoring variables (the RI 
and/or the number of episodes longer than 5 minutes 
and/or the Jolley score) in all treatment groups, the me-
dian total reflux time and RI were significantly lower in 
group A than that in the other groups. The total reflux 
time after treatment in group B and group C were not 
significantly different from that in the placebo group. 
Clinically, the patients in group A were significantly im-
proved compared to those in the other groups. The au-
thors concluded that the combination of domperidone 
plus Mg hydroxide and Al hydroxide was more effective 
than the other treatments. However, the administration 
of a thickening agent in all groups, Medigel 1%, may have 
been a confounding factor for the significant improve-
ment of the pH parameters in the placebo group.
In 2002, Borrelli et al. (113) enrolled 36 children (median 
age 5.6 years, range 12 months to 12 years) with a diag-
nosis of GERD based on symptoms, 24-hour pH monitor-
ing and endoscopy. Participants were randomly assigned 
to three groups: alginate alone (2 mL/kg/day in divided 
doses), lansoprazole 1.5 mg/kg twice daily before meals 
or lansoprazole + alginate with the same doses as above. 
Patients with severe esophagitis received high-dose lan-
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soprazole without randomization. Patients underwent 
24-hour pH monitoring at one week, symptomatic eval-
uation at four weeks and symptom assessment with en-
doscopy at eight weeks. Although significant symptom 
improvements were noted, based on 24-hour pH mon-
itoring and endoscopy (p<0.01) in the patients with EE 
who received alginate alone, the alginate and lansopra-
zole combination achieved significantly better symptom 
improvement compared to that in the other two groups 
(p<0.01). The improvement in the RI in the alginate and 
lansoprazole group was significantly superior to that in 
the other two groups (p<0.05).
In 2005, 20 infants (mean age 163.5 days; range 34-319 
days) who were exclusively bottle-fed and had symptoms 
suggestive of GER (regurgitation >3x/day, any amount; or 
>once/day, half a feed), underwent 24-hour MII stud-
ies and dual-channel pH monitoring (114). The infants 
received six random (3+3) Gaviscon Infant (625 mg in 
225 mL milk, powder formulation not containing HCO3) 
or placebo (mannitol and Solvito N, 625 mg in 225 mL) 
doses in a double-blind fashion. Gaviscon Infant consists 
of Na and Mg alginate and mannitol; it does not contain 
HCO3. The observer interpreting the data was also blind-
ed. In the infants that received Gavison Infant, only the 
reflux height improved, without other significant differ-
ences, when compared to the infants who received a pla-
cebo. In contrast to some studies, these results suggest 
that Gaviscon Infant has little effect on GER when it is 
assessed in objective terms. However, the dosage used 
in this study was lower than that recommended by the 
manufacturer, which may have influenced the results. 
Sleep and wakefulness may also affect GER episodes 
and may lessen the differences, as shown previously 
(115), and meals without and with alginate were altered, 
possibly inducing an ongoing effect of alginate during a 
drug-free meal. Additionally, the absence of HCO3 in the 
preparation that the researchers used prevented the for-
mation of a raft, thus the treatment acted as a thickening 
agent only. Although it was stated that all patients con-
sumed 225 mL milk 6 times daily (1350 mL/day), it does 
not seem possible for a 34-day-old baby to consume that 
amount of milk. There were no data on the baseline pa-
rameters or on the improvement in GERD symptoms, so 
no conclusions about the improvement in GERD symp-
toms could be made.
Miller (116) conducted a phase III, multicenter, dou-
ble-blind randomized controlled study comparing Gavis-
con Infant (Al-free, Na alginate 225 mg and Mg alginate 
87.5 mg in each sachet) vs placebo, which included 90 
infants (aged 0 to 12 months). The inclusion criteria 
were the presence of symptoms consistent with GER at 
least twice daily for the two days prior to the start of the 
study. The exclusion criteria were the presence of known 
esophageal/GI disease, weighing less than 2.5 kg or pre-
maturity. Bottle-fed infants weighing <4.5 kg were giv-
en one sachet in at least 115 mL of food and those who 
were ≥4.5 kg were given two sachets in at least 225 mL 
of food. Breastfed infants received the same amount of 
drug in 15 mL of water. Patients were reassessed after 
seven and 14 days. The improvement in symptoms and 
quantified vomiting/regurgitation episodes over the pre-
vious 24 hours (from none to severe (three)) were record-
ed. Forty-two of the patients were randomized to receive 
alginate, and 48 were randomized to receive placebo. 
There were 20 withdrawals from the study (alginate 7 and 
placebo 13, p>0.2). The adverse events were not different 
in the alginate and placebo groups, and four patients in 
the alginate group and 7 patients in the placebo group 
were withdrawn from the study due to adverse events. 
Alginate was significantly superior to placebo in terms of 
the improvement in symptoms (investigators p=0.008 
and parents p=0.002) and the number of vomiting epi-
sodes (p=0.009). Alginate caused a trend in a reduction in 
the severity of vomiting (p=0.061), and alginate achieved 
a significantly greater reduction in the mean severity of 
vomiting episodes (p=0.027) and resulted in more pa-
tients having at least 10% symptom-free days (p=0.027) 
compared to the placebo. The follow-up in this study was 
short, and the total daily doses were not reported. Thus, 
a symptom improvement may not represent an improve-
ment in GER.
Ummarino et al. (117) compared the effect of Mg alginate 
plus simethicone (Gastrotuss Baby, DMG Italia SRL, Pro-
mezia, Italy; Al-free) with rice-starch-thickened formula 
in infants with GER. In this randomized controlled trial, 
full-term babies with symptoms suggestive of GER were 
evaluated with a validated questionnaire (Infant Gastro-
esophageal Reflux Questionnaire Revised-I-GERQ) and 
those with a symptomatic score ≥7 were enrolled in this 
study. The patients were randomized into three groups: 
group A (25 patients), Mg alginate plus simethicone (2.5 
mL 3 times/day for infants weighing <5 kg or 5 mL 3 
times a day for those weighing >5 kg, given 10 minutes 
after eating); group B (25 patients), rice-starch-thick-
ened formula (14.3 g rice starch per 100 mL milk for in-
fants younger than 6 months and 14.2 g per 100 mL of 
milk for older infants), and group C (25 patients), advice 
on lifestyle changes. The response was evaluated after 1 
month and 2 months. Sixty-four (85.3%) of the 75 en-
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rolled infants (median age 5 months; range 1-10) com-
pleted the study. After one month of treatment, group 
A patients showed a statistically significant improvement 
in symptoms compared with group B (p<0.03) and group 
C (p<0.0001) patients. The median symptom score also 
significantly decreased (p<0.02) in group B at one month 
but was not significantly different in group C (p<0.07). 
At the end of the study, although all three groups of pa-
tients showed a significant reduction in symptom scores 
(p<0.002, p<0.038, and p<0.03, respectively), the me-
dian symptom score values were more significantly re-
duced in group A than in group B (p<0.002) and group C 
(p<0.0001) and in group B than in group C (p<0.001). At 
the end of one month of treatment, 48% of the patients 
in group A, 16% of the patients in group B, and none of 
the patients in group C were free of symptoms.
c. Use of alginate-based formulations in neonates and 
preterm infants
At present, there is no consensus on the pharmacological 
treatment of GER in preterm newborns. The most com-
monly used drugs are alginate formulations, H2RA and 
PPIs (118).
Atasay et al. (119) evaluated the effect of Na alginate on 
preterm infants. They enrolled 41 preterm infants with a 
clinical diagnosis of GER, and 34 (83%) of these patients 
had pathologic measurements on 24-hour pH monitor-
ing. There was no significant difference between patients 
who did and did not have pathologic measurements in 
regard to gestational age, birth weight, and postnatal age 
and weight on the day of pH monitoring (p>0.05). Four 
times a day, 1 mL/kg of Na alginate with KHCO3 was ad-
ministered to the patients with pathologic pH measure-
ments and pH monitoring was repeated after 48 hours of 
treatment. The major outcomes were an improvement in 
the number of reflux events per 24 hours, the duration of 
the longest episode, the number of episodes >5 minutes, 
and the RI. Twenty-seven (79.4%) of the 34 patients re-
sponded to treatment. Treatment with Na alginate sig-
nificantly improved the number of episodes per 24 hours, 
the RI, the number of episodes >5 minutes and the dura-
tion of the longest episode. Patients were also evaluated 
for vomiting and weight gain 1 week after the treatment. 
The frequency of vomiting decreased and weight gain im-
proved.
Corvaglia et al. (120) evaluated the effect of sodium al-
ginate on GER features in preterm babies by MII-pHM. 
Thirty-two symptomatic preterm infants underwent a 
24-hour MII-pHM during which each baby was fed eight 
times. Sodium alginate (0.25 mL/kg/dose) was given four 
times at alternating meals; drug-given (DG) vs drug-free 
(DF) meals. The 2nd, 4th, 6th and 8th meals were DG, where-
as the remaining were DF. Sodium alginate significantly 
decreased the number of acid GER detected either by pH 
monitoring (p=0.002) and MII-pHM (p=0.050), as well as 
the acid esophageal exposure (p=0.030), without any in-
fluence on non-acid GER. Furthermore, sodium alginate 
decreased the number of cases of GER reaching the prox-
imal esophagus (p=0.030). The use of sodium alginate in 
preterm infants seems to be promising because this drug 
decreases GER acidity and height and has the advantage 
of having a non-systemic method of action and a more 
favorable safety profile than H2RA and PPIs. The design of 
this study did not allow an adequate evaluation of reflux 
symptoms because of the limited duration of MII-pHM.
In another study conducted by Corvaglia et al. (121) on 
preterm infants (gestational age ≤33 weeks, weight 
≥1100 g, on full enteral feeding) with apneas related to 
GER. Twenty-eight preterm infants (postnatal age me-
dian 35 weeks, range 32-42 weeks) with apnea of pre-
maturity (AOP) were studied by a six-hour MII-pHM re-
cording and polysomnography, including two three-hour 
postprandial periods. Na alginate (Gaviscon 0.25 mL/kg 
with NaHCO3) was given after a single meal, referred to 
as the DG meal, while the other meal was referred to as 
the DF meal. The DG meal was randomly chosen. Na al-
ginate administration did not decrease the number of 
AOP (p=0.99) events. A significant reduction in the num-
ber of acid GER (pH<4) events and in acid exposure was 
found during DG, while the administration of Na alginate 
did not influence non-acid GER indexes. DG periods also 
significantly reduced the number of proximal GER events 
(p<0.0001) as well as reducing the distal acid GERs de-
tected by MII-pHM (p=0.003). The reason that a drug 
that acts on acid GER is ineffective in reducing apneas is 
probably related to peculiar GER features. Recently, some 
authors have hypothesized that reflux triggers apnea only 
under certain circumstances that still remain to be iden-
tified and that only certain types of refluxed material may 
induce apnea: specifically, it has been stated that “the 
acidity, volume, or pressure of the refluxed material could 
determine the respiratory response”.
In Corvaglia et al. (120,121) studies, meals with and with-
out alginate were alternated, possibly inducing a carry-
over effect of alginate during a drug-free meal.
The investigation and management of GER in neonatal 
intensive care units (NICU) widely varies. In 2017, Rossor 
S130
Bor et  a l .  Alginates in GERD Turk J  Gastroenterol  2019;  30(Suppl  2) :  S109-36
et al. (118) sent a questionnaire to all 207 United Kingdom 
neonatal units, and responses were obtained from 84% 
of units. To establish a diagnosis, 58% of units used a tri-
al of treatment, and Gaviscon was the most commonly 
(60%) used drug followed by ranitidine (53%). Investiga-
tions including pH monitoring (24%), GI contrast studies 
(23%), MII-pHM (6%), abdominal ultrasonography (3%) 
and gastroesophageal scintigraphy (2%) were used less 
frequently. The thresholds for an abnormal pH study and/
or MII-pHM study were also different among the units. 
Only two units never started antireflux medication prior 
to investigations, and 32% of the units started medica-
tion without investigations.
Briefly, in preterm babies, alginates decreased the num-
ber of vomiting episodes and improved weight gain (119), 
improved pH monitoring variables, particularly acidic re-
flux events (119-121), and decreased reflux events that 
reached the proximal esophagus (120,121). Although 
there is a case report showing that alginate may resolve 
AOP (122), Corvaglia et al’s study did not show any bene-
ficial effect of alginates on AOP (120).
The routine use of alginates in preterm infants needs to 
be more thoroughly studied before its routine use can be 
recommended in this special population.
Side effects
There are very few studies about the adverse effects of 
alginates in childhood. Nevertheless, alginates seem to 
have no severe/significant side effects. Although diar-
rhea, teething syndrome, nausea and vomiting, constipa-
tion, colic, fever, and acute nasopharyngitis are the most 
commonly reported adverse effects, their frequencies 
were not significantly different (p>0.02) from those of 
placebo (116).
Na-containing formulations should be prescribed with 
caution to preterm babies and to people with cardiac fail-
ure, renal impairment, diarrhea and vomiting (123). For-
mulations containing Al may cause increased serum Al 
plasma concentrations (124,125). Fortunately, there are 
currently no Al-containing commercial formulations.
Gaviscon may rarely cause Gaviscon bezoars (gaviscono-
ma), and the combined use of thickening agents increas-
es this risk. In that case, the drug should be immediately 
stopped (126). When dehydration is likely due to exces-
sive water loss or when there is a risk of intestinal ob-
struction, alginate formulations should not be used (123). 
HCO3-containing formulations may cause hypokalemic 
metabolic alkalosis when taken at high doses and in the 
presence of vomiting (127). Alginate-based agents may 
decrease the Ca and iron availability (128).
Conclusion
Current data suggest that alginates are moderately ef-
fective in the treatment of GER in childhood. In the ma-
jority of these studies, alginate administration improved 
clinical symptoms, such as regurgitation, the incidence 
and severity of vomiting, crying and fussiness in both 
studies without control groups (102-104,107) and with 
control groups (109-113,116,117).
Four studies showed that alginates reduce the number of 
refluxes that reach the proximal esophagus and the height 
of the refluxate in the esophagus (107,114,120,121). When 
alginates contain HCO3, alginates decrease the acidity of 
the reflux, showing the same efficacy as acid suppressors 
(117). Compared to H2RA and PPIs, alginate-based formu-
lations are less effective for the treatment of esophagitis 
(37). There are many controversial studies on the effect 
of alginates on MII-pHM and/or pH recording parameters, 
and studies on children are scarce. Although there are 
controversial reports (108,114), alginate administration 
decreases the number of refluxes (particularly acidic re-
fluxes), the RI, the number of reflux episodes lasting >5 
minutes, and the duration of the longest reflux episodes 
(110-113,116,117).
It is hard to interpret and compare these studies; the con-
tents and dosages of alginate formulations used in the 
trials, the designs and outcome parameters, and the ages 
of the populations are different. Most of these studies 
were in infants, and the natural tendency of GER to im-
prove over time may have influenced some of the results.
Alginate is widely used in children, including neonates 
and premature babies, without serious adverse effects. 
Further well-designed studies on the effect of alginates 
on the clinical and laboratory characteristics of reflux are 
needed.
Use of alginates for the treatment of gastroesophageal 
reflux disease in pregnancy and lactation
Heartburn occurs frequently in pregnancy (30%-50%), 
and it becomes more common in the third trimester. 
There are several mechanisms causing GERD in pregnan-
cies. A significant decrease in lower esophageal sphinc-
ter pressure, elevated intraabdominal pressure, increased 
progesterone levels and delayed intestinal transit are the 
leading causes of GERD in pregnancy (129).
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Alginate builds a nonsystemic, strong, raft-like barrier 
against the reflux of acid and food into the esophagus. 
Since it is a nonsystematic agent, theoretically alginate 
appears to be a safe choice for the treatment of GERD 
in pregnancy. In an open-labeled multicentered study, 
the use of alginate for over 4 weeks resulted in satis-
factory treatment endpoints, while fetal distress was 
observed in only 3 fetuses (130). In another two-center 
(South Africa and United Kingdom) prospective study, 
fetus-related perinatal morbidity and mortality rates 
were comparable to that in the normal population with 
alginate therapy, given at a maximum dose of 80 mL/
day for 4 weeks (131). In a more recent study, alginate 
and antacids were compared with 50 pregnant women 
in each group, and no difference was found between 
groups in terms of the pregnancy and neonatal out-
comes (132).
There are extremely limited data concerning the use of 
GERD drugs during the lactation period, and the data are 
anecdotal. Since it is not systemically absorbed, alginate 
was recommended for GERD treatment during the lacta-
tion period in the Turkish Reflux Study Group Consensus 
Report (129).
In conclusion, during pregnancy and lactation, alginate 
can be recommended as a first-level treatment agent.
Safety of alginates
To the best of our knowledge, to date, there has been 
no study in the literature that has aimed to analyze the 
safety of alginate as a primary study endpoint. However, 
there are satisfactory indirect data from efficacy studies 
confirming that alginate is a safe agent for the treatment 
of GERD.
In a placebo-controlled study, 13 adverse events oc-
curred in 3 patients in the alginate group, and 19 ad-
verse events were seen in 11 patients in the placebo 
arm. The treatments were generally well tolerated, and 
no serious adverse events were reported in either group 
(46). A low incidence of adverse events was observed 
in another study comparing alginate (5.4%) and ome-
prazole (5.5%). The severity of all adverse events was 
mild or moderate, and no severe adverse events were 
reported during the study period (44). Pouchain et al. 
(39) showed that omeprazole and alginate were com-
parable in terms of safety. At least one adverse event 
was reported in 12.6% of the alginate group, while it was 
reported in 14.2% of the omeprazole group. One se-
vere adverse event occurred in the omeprazole group, 
and there were no severe adverse events in the alginate 
group. In a prospective randomized study, three (4.35%) 
patients in the alginate group and four (6.12%) patients 
in the antacid group had at least one adverse event. No 
dosage modification was applied for the three adverse 
events in the alginate group, while two of the four ad-
verse events in antacid-treated patients led to a dose 
reduction of the medication. No serious adverse events 
were reported during the entire study period (38).
In conclusion, the safety profile of alginates is compara-
ble to that of placebo/antacid or PPIs, and according to 
the current literature, no serious adverse events were ob-
served during alginate treatment.
Conclusion
In this expert opinion paper, we evaluated the different 
aspects of alginate treatment in patients with GERD. It is 
possible to conclude from the existing studies that:
1. According to the production methods, each alginate 
has different characteristics, and it is not possible to 
replace an alginate from one source with one from 
another source. Basic science studies showed that 
Laminaria hyperborea was able to form strong, co-
herent, voluminous and highly buoyant rafts com-
pared to others.
2. Alginate has a unique mode of action, producing raft 
formation. The effect is fast.
3. Alginate monotherapy is a preferable option for the 
treatment of mild GERD symptoms.
4. In patients with severe or breakthrough symptoms 
in PPI-unresponsive GERD, alginates can be used in 
combination with PPIs to improve symptoms and to 
reduce reflux events.
5. Although more data are needed, the efficacy in re-
gurgitation-dominant GERD is possibly higher with 
alginates.
6. Alginates have a place in the management of atypical 
GERD symptoms.
7. Alginate can be used either long term and/or on-de-
mand therapy following the cessation of PPIs.
8. In the treatment of GERD in children, alginates have a 
proven and efficient effect and are safe.
9. Alginates can be used in pregnancy and lactation as a 
first-line therapy.
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